Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ: ADMA )

15.90 -0.18 (-1.12%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,741,152
Open 16.15
Bid (Size) 15.80 (3)
Ask (Size) 16.01 (3)
Prev. Close 16.08
Today's Range 15.72 - 16.15
52wk Range 5.020 - 23.64
Shares Outstanding 196,357,149
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business." 
Via Benzinga
Peering Into ADMA Biologics's Recent Short Interest
Via Benzinga

Performance

YTD
-11.52%
-11.52%
1 Month
-4.39%
-4.39%
3 Month
-18.63%
-18.63%
6 Month
-12.73%
-12.73%
1 Year
+201.14%
+201.14%

More News

Read More
There May Still Be Time to Get in on These 3 Trending Biotechs
Via MarketBeat
Topics ETFs Economy
Exposures Economy Interest Rates
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
Via Investor's Business Daily
ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
How Is The Market Feeling About ADMA Biologics?
Via Benzinga
Looking Into ADMA Biologics's Recent Short Interest
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
SpringWorks Therapeutics Stock Gets A RS Rating Lift
Via Investor's Business Daily
ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025
From ADMA Biologics, Inc.
Via GlobeNewswire
Arcellx Stock Earns 82 Relative Strength Rating
Via Investor's Business Daily
ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
Via ACCESSWIRE
The Schall Law Firm Invites Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations
Via ACCESSWIRE
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
BioNTech Stock Got A IBD RS Rating Lift
Via Investor's Business Daily
ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
While growth is established for NASDAQ:ADMA, the stock's valuation remains reasonable.
Via Chartmill
Vericel Stock Sees RS Rating Shoot Higher
Via Investor's Business Daily
Kirby McInerney LLP Reminds ADMA Biologics, Inc. (ADMA) Investors of Shareholder Investigation
From Kirby McInerney LLP
Via Business Wire
ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against ADMA Biologics, Inc. (ADMA)
From Kirby McInerney LLP
Via Business Wire
ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Buckle Up And Use Volitility To Your Advantage
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.